Afimoxifene

Afimoxifene

Names
IUPAC name (Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
Other names 4-hydroxytamoxifen
Identifiers
CAS Number	68392-35-8 N
ChEMBL	ChEMBL489 Y
ChemSpider	395987 Y
Jmol 3D model	Interactive image Interactive image
KEGG	D06551 Y
PubChem	449459
UNII	17197F0KYM Y
InChI InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25- Y Key: TXUZVZSFRXZGTL-QPLCGJKRSA-N Y InChI=1/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25- Key: TXUZVZSFRXZGTL-QPLCGJKRBX
SMILES CC\C(c1ccccc1)=C(c2ccc(OCCN(C)C)cc2)/c3ccc(O)cc3 O(c1ccc(cc1)/C(c2ccc(O)cc2)=C(\c3ccccc3)CC)CCN(C)C
Properties
Chemical formula	C26H29NO2
Molar mass	387.51396
Vapor pressure	{{{value}}}
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Afimoxifene (4-hydroxytamoxifen) is a selective estrogen receptor modulator which is the active metabolite of tamoxifen. Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel.

Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia.

A study in France on 55 women showed that rubbing afimoxifene on the skin was as good as tamoxifen tablets at slowing breast cancer growth. A US trial will compare 6 weeks use before breast cancer surgery. Skin application can reduce systemic levels by a factor of nine and this is expected to reduce the unpleasant side-effects of tamoxifen.

External links

• 4-hydroxytamoxifen at the US National Library of Medicine Medical Subject Headings (MeSH)